lnc-MTRNR2L12-3 derived from hypoxic breast cancer cell exosomes facilitates angiogenesis via the Src/FAK signaling pathway
- PMID: 40560294
- DOI: 10.1007/s12032-025-02836-9
lnc-MTRNR2L12-3 derived from hypoxic breast cancer cell exosomes facilitates angiogenesis via the Src/FAK signaling pathway
Abstract
Exosomal long non-coding RNAs (lncRNAs) play crucial roles in breast cancer progression. However, the mechanisms by which hypoxia-induced exosomes mediate angiogenesis through lncRNAs in the tumor microenvironment remain largely unexplored. In this study, exosomes were isolated and characterized from MDA-MB-231 breast cancer cells under normoxic and hypoxic conditions. Hypoxia-induced exosomes (Hyp-exo) were shown to significantly promote angiogenesis. Microarray analysis revealed that lnc-MTRNR2L12-3 was highly enriched in Hyp-exo compared to normoxic exosomes (NC-exo). Functional studies, both in vitro and in vivo, demonstrated that exosomal lnc-MTRNR2L12-3 derived from hypoxic breast cancer cells substantially enhanced angiogenesis. Mechanistically, PCR array and western blot analysis confirmed that silencing lnc-MTRNR2L12-3 inhibited Src/FAK signaling pathway activation in HUVECs, while hypoxia-induced exosomes effectively rescued this suppression. Overall, hypoxia-induced breast cancer exosomes deliver lnc-MTRNR2L12-3 to endothelial cells, promoting angiogenesis through the Src/FAK signaling pathway. These findings provide new insights into targeting angiogenesis in the tumor microenvironment for breast cancer therapy.
Keywords: Angiogenesis; Breast cancer; Exosome; Hypoxia; Lnc-MTRNR2L12-3; Src/FAK signaling pathway.
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Conflict of interest: The authors declare no competing interests. Ethical approval: All protocols involving animal experiments were proved strictly by Medical Ethics Committee of the Second Affiliated Hospital of Jiaxing University. The study was conducted in accordance with the local legislation and institutional requirements.
Similar articles
-
Exosome-derived lnc-FAM72D-3 promotes lenvatinib resistance by remodeling hepatocellular carcinoma cytoskeleton via MBNL1/FAK axis.Drug Resist Updat. 2025 Sep;82:101271. doi: 10.1016/j.drup.2025.101271. Epub 2025 Jun 7. Drug Resist Updat. 2025. PMID: 40517686
-
Hypoxic mesenchymal stem cell-derived exosomes promote bone fracture healing by the transfer of miR-126.Acta Biomater. 2020 Feb;103:196-212. doi: 10.1016/j.actbio.2019.12.020. Epub 2019 Dec 17. Acta Biomater. 2020. PMID: 31857259
-
Exosomal lncRNA SNHG12 promotes angiogenesis and breast cancer progression.Breast Cancer. 2024 Jul;31(4):607-620. doi: 10.1007/s12282-024-01574-6. Epub 2024 Jun 4. Breast Cancer. 2024. PMID: 38833118 Free PMC article.
-
Unveiling the functional paradigm of exosome-derived long non-coding RNAs (lncRNAs) in cancer: based on a narrative review and systematic review.J Cancer Res Clin Oncol. 2023 Nov;149(16):15219-15247. doi: 10.1007/s00432-023-05273-1. Epub 2023 Aug 14. J Cancer Res Clin Oncol. 2023. PMID: 37578522 Free PMC article.
-
Exosomes in hypoxia: generation, secretion, and physiological roles in cancer progression.Front Immunol. 2025 Jun 4;16:1537313. doi: 10.3389/fimmu.2025.1537313. eCollection 2025. Front Immunol. 2025. PMID: 40534881 Free PMC article. Review.
References
-
- Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660 . - DOI
-
- Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12–49. https://doi.org/10.3322/caac.21820 . - DOI
-
- Giaquinto AN, Sung H, Newman LA, et al. Breast cancer statistics 2024. CA Cancer J Clin. 2024;74(6):477–95. https://doi.org/10.3322/caac.21863 . - DOI
-
- Kaklamani VG, Arteaga CL. Breast cancer: the good, the bad, and an important call to effective risk reduction strategies. CA Cancer J Clin. 2024;74(6):471–4. https://doi.org/10.3322/caac.21867 . - DOI
-
- Roskoski RJ. Targeted and cytotoxic inhibitors used in the treatment of breast cancer. Pharmacol Res. 2024;210:107534. https://doi.org/10.1016/j.phrs.2024.107534 . - DOI
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous